Cargando…

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition

Detalles Bibliográficos
Autores principales:	Pepper, C, Buggins, A G S, Jones, C H, Walsby, E J, Forconi, F, Pratt, G, Devereux, S, Stevenson, F K, Fegan, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360209/ https://www.ncbi.nlm.nih.gov/pubmed/25349153 http://dx.doi.org/10.1038/leu.2014.308

Ejemplares similares

Celebrating 20 Years of IGHV Mutation Analysis in CLL
por: Chiorazzi, Nicholas, et al.
Publicado: (2020)

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
por: Walsby, Elisabeth, et al.
Publicado: (2012)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
por: Bond, David A, et al.
Publicado: (2020)

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
por: Pepper, Andrea G. S., et al.
Publicado: (2021)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL
por: Bryant, Dean, et al.
Publicado: (2023)

P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
por: Vit, Filippo, et al.
Publicado: (2023)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
por: Lew, Thomas E., et al.
Publicado: (2021)

Flow cytometry as a fast, cost-effective tool to assess IGHV mutational status in CLL
por: Couillez, Guillaume, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease
por: Rose-Zerilli, M J J, et al.
Publicado: (2016)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
por: Trummer, Arne, et al.
Publicado: (2022)

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells
por: Rigoni, Micol, et al.
Publicado: (2015)

HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis
por: García-Álvarez, María, et al.
Publicado: (2017)

Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity
por: Sofou, Electra, et al.
Publicado: (2022)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

Identification of proliferative and non-proliferative subpopulations of leukemic cells in CLL
por: Cuthill, Kirsty M., et al.
Publicado: (2022)

Telomere length predicts for outcome to FCR chemotherapy in CLL
por: Norris, Kevin, et al.
Publicado: (2019)

Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells
por: Ramdas, Baskar, et al.
Publicado: (2022)

Telomere fusions associate with coding sequence and copy number alterations in CLL
por: Escudero, Laura, et al.
Publicado: (2019)

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL
por: Rogers, Andrew, et al.
Publicado: (2020)

The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors
por: Sampietro, Marta, et al.
Publicado: (2023)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2019)

Variant B Cell Receptor Isotype Functions Differ in Hairy Cell Leukemia with Mutated BRAF and IGHV Genes
por: Weston-Bell, Nicola J., et al.
Publicado: (2014)

NF-kB and the CLL microenvironment
por: O’Donnell, Alice, et al.
Publicado: (2023)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status
por: Shea, Lauren K., et al.
Publicado: (2019)

Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay
por: Mimmi, Selena, et al.
Publicado: (2022)

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
por: St-Pierre, Frédérique, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0h5uk5gom5hvon3j2nu0aoq0n3